Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 24;22(21):11464.
doi: 10.3390/ijms222111464.

Epigenetic Dysregulations in Merkel Cell Polyomavirus-Driven Merkel Cell Carcinoma

Affiliations
Review

Epigenetic Dysregulations in Merkel Cell Polyomavirus-Driven Merkel Cell Carcinoma

John Charles Rotondo et al. Int J Mol Sci. .

Abstract

Merkel cell polyomavirus (MCPyV) is a small DNA virus with oncogenic potential. MCPyV is the causative agent of Merkel Cell Carcinoma (MCC), a rare but aggressive tumor of the skin. The role of epigenetic mechanisms, such as histone posttranslational modifications (HPTMs), DNA methylation, and microRNA (miRNA) regulation on MCPyV-driven MCC has recently been highlighted. In this review, we aim to describe and discuss the latest insights into HPTMs, DNA methylation, and miRNA regulation, as well as their regulative factors in the context of MCPyV-driven MCC, to provide an overview of current findings on how MCPyV is involved in the dysregulation of these epigenetic processes. The current state of the art is also described as far as potentially using epigenetic dysregulations and related factors as diagnostic and prognostic tools is concerned, in addition to targets for MCPyV-driven MCC therapy. Growing evidence suggests that the dysregulation of HPTMs, DNA methylation, and miRNA pathways plays a role in MCPyV-driven MCC etiopathogenesis, which, therefore, may potentially be clinically significant for this deadly tumor. A deeper understanding of these mechanisms and related factors may improve diagnosis, prognosis, and therapy for MCPyV-driven MCC.

Keywords: DNA methylation; HPTMs; Merkel cell carcinoma (MCC); Merkel cell polyomavirus (MCPyV); epigenetics; histone posttranslational modifications; miRNA; microRNA; virus-driven tumors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Epigenetic mechanisms. Epigenetic mechanisms comprise (A) histone posttranslational modifications (HPTMs), (B) DNA methylation, and (C) microRNAs (miRNAs) regulation. Gene expression can be regulated before transcription initiation by HPTMs and DNA methylation. Both mechanisms induce a remodeling of the chromatin structure, thereby making genes either less or more accessible for transcription factors, according to the different epigenetic modifications. Unlike DNA methylation and HPTMs, miRNAs regulate the expression of genes at the post-transcriptional level. miRNAs negatively regulate genes through complementing their mRNAs, which results in mRNA degradation or translational repression.
Figure 2
Figure 2
Impairment of epigenetic mechanisms in Merkel cell polyomavirus (MCPyV)-driven Merkel cell carcinoma. MCPyV sT promotes LSD1 expression through histone acetylation activation to induce cellular transformation. MCPyV sT can induce H2AX phosphorylation and H3K4 and H4K20 dimethylation (H3K4me2 and H4K20me2), thereby leading to the DNA damage response pathway activation. Tumor suppressor genes silencing via H3K27me3 mark might be a mechanism in MCPyV-driven MCC tumorigenesis. Loss of HLA class-I and MICA/B expression via H3K9 deacetylation might represent a strategy to evade the antiviral/-tumoral immune response. MCPyV LT/sT expression can upregulate miRNAs targeting genes involved in autophagy/cell death, such as ATG7, SQSTM1/p62, and BECN1. Continuous arrows—epigenetic dysregulation determined functionally in vitro. Dashed arrows—hypothesized epigenetic mechanisms. LT/sT (?)—the role of MCPyV LT/sT proteins has not been demonstrated.

References

    1. Feng H., Shuda M., Chang Y., Moore P.S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–1100. doi: 10.1126/science.1152586. - DOI - PMC - PubMed
    1. Rotondo J.C., Bononi I., Puozzo A., Govoni M., Foschi V., Lanza G., Gafa R., Gaboriaud P., Touzé F.A., Selvatici R., et al. Merkel cell carcinomas arising in autoimmune disease affected patients treated with biologic drugs including anti-TNF. Clin. Cancer Res. 2017;23:3929–3934. doi: 10.1158/1078-0432.CCR-16-2899. - DOI - PubMed
    1. Jin H.T., Park S.J., Choi E.K., Kim Y.S. The frequency of Merkel cell polyomavirus in whole blood from immunocompetent and immunosuppressed patients with kidney disease and healthy donors. Microb. Pathog. 2019;131:75–80. doi: 10.1016/j.micpath.2019.03.020. - DOI - PubMed
    1. Lewis C.W., Qazi J., Hippe D.S., Lachance K., Thomas H., Cook M.M., Juhlin I., Singh N., Thuesmunn Z., Takagishi S.R., et al. Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance. Cancer Med. 2020;9:1374–1382. doi: 10.1002/cam4.2781. - DOI - PMC - PubMed
    1. Zwijnenburg E.M., Lubeek S.F.K., Werner J.E.M., Amir A.L., Weijs W.L.J., Takes R.P., Pegge S.A.H., van Herpen C.M.L., Adema G.J., Kaanders J.H.A.M. Merkel cell carcinoma: New trends. Cancers. 2021;13:1614. doi: 10.3390/cancers13071614. - DOI - PMC - PubMed

LinkOut - more resources